120 related articles for article (PubMed ID: 31293154)
1. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro.
Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX
Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154
[TBL] [Abstract][Full Text] [Related]
2. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
[TBL] [Abstract][Full Text] [Related]
4. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
6. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
7. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
[TBL] [Abstract][Full Text] [Related]
9. Functional Analysis of Wild-Type and 27 CYP3A4 Variants on Dronedarone Metabolism
Wang CC; Lan T
Curr Drug Metab; 2022; 23(7):562-570. PubMed ID: 35702776
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Kinetic Characterization of Axitinib Metabolism.
Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ
Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
[TBL] [Abstract][Full Text] [Related]
11. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA
Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381
[TBL] [Abstract][Full Text] [Related]
12. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
13. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).
Haigentz M; Lee JY; Chiao EY; Aboulafia DM; Ratner L; Ambinder RF; Baiocchi RA; Mitsuyasu RT; Wachsman W; Sparano JA; Rudek MA
Clin Cancer Res; 2023 Dec; 29(24):5038-5046. PubMed ID: 37523145
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.
Maekawa K; Yoshimura T; Saito Y; Fujimura Y; Aohara F; Emoto C; Iwasaki K; Hanioka N; Narimatsu S; Niwa T; Sawada J
Xenobiotica; 2009 Feb; 39(2):140-7. PubMed ID: 19255940
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP
Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111
[TBL] [Abstract][Full Text] [Related]
17. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
18. Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro.
Lin QM; Li YH; Liu Q; Pang NH; Xu RA; Cai JP; Hu GX
Infect Drug Resist; 2019; 12():2809-2817. PubMed ID: 31571937
[TBL] [Abstract][Full Text] [Related]
19. Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b
Indra R; Vavrová K; Pompach P; Heger Z; Hodek P
Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33260548
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the substrate kinetics of pig CYP3A29 with pig liver microsomes and human CYP3A4.
Yao M; Dai M; Liu Z; Huang L; Chen D; Wang Y; Peng D; Wang X; Liu Z; Yuan Z
Biosci Rep; 2011 Jun; 31(3):211-20. PubMed ID: 20863320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
